vendredi 19 mai 2017

21 trisomy


Down syndrome (DS) is the commonest genetic cause of mental disability.
Epigenetic modifications are implicated in neurocognitive dysfunction in DS.
These epigenetic modifications are suitable therapeutic targets, but current therapies may have unwanted side effects.
CRISPR-Cas9 is a precise genome editing technology that could be used to target epigenomic abnormalities in DS.
A number of barriers − both technical and ethical − will need to be overcome for clinical translation.

Aucun commentaire: